Skip to main content

Table 3 GENEDIAB cohort: Plasma EC-SOD, AOPP and Isoprostane concentrations by clinical outcomes during follow-up

From: Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes

 

N

EC-SOD (ng/ml)

N

AOPP (μmol/l)

N

Isoprostane (ng/ml)

Myocardial infarction

Yes

25

194 ± 44

26

60 ± 6

26

2.37 ± 0.24

No

208

196 ± 15

214

66 ± 2

226

1.52 ± 0.08

p

 

0.51

 

0.49

 

0.0003

All-cause mortality

Yes

47

195 ± 30

40

73 ± 6

42

2.22 ± 0.20

No

194

192 ± 14

209

56 ± 4

221

1.71 ± 0.12

p

 

0.57

 

0.004

 

0.002

  1. Results expressed as mean ± SEM. Statistics are ANCOVA adjusted for sex, age, BMI, systolic blood pressure and eGFR (EC-SOD), for sex, age, total cholesterol concentration, and use of ACE inhibitors (AOPP), and for sex, age, diastolic blood pressure, and use of lipid lowering drugs (isoprostane). p < 0.05 is significant.